Skip to Content
Merck
  • In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Antimicrobial agents and chemotherapy (2014-11-12)
Michael D Huband, Patricia A Bradford, Linda G Otterson, Gregory S Basarab, Amy C Kutschke, Robert A Giacobbe, Sara A Patey, Richard A Alm, Michele R Johnstone, Marie E Potter, Paul F Miller, John P Mueller
ABSTRACT

AZD0914 is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-negative (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with known resistance to fluoroquinolones. AZD0914 works via inhibition of DNA biosynthesis and accumulation of double-strand cleavages; this mechanism of inhibition differs from those of other marketed antibacterial compounds. AZD0914 stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand cleaved DNA to form fused circular DNA. Whereas this mechanism is similar to that seen with fluoroquinolones, it is mechanistically distinct. AZD0914 exhibited low frequencies of spontaneous resistance in S. aureus, and if mutants were obtained, the mutations mapped to gyrB. Additionally, no cross-resistance was observed for AZD0914 against recent bacterial clinical isolates demonstrating resistance to fluoroquinolones or other drug classes, including macrolides, β-lactams, glycopeptides, and oxazolidinones. AZD0914 was bactericidal in both minimum bactericidal concentration and in vitro time-kill studies. In in vitro checkerboard/synergy testing with 17 comparator antibacterials, only additivity/indifference was observed. The potent in vitro antibacterial activity (including activity against fluoroquinolone-resistant isolates), low frequency of resistance, lack of cross-resistance, and bactericidal activity of AZD0914 support its continued development.

MATERIALS
Product Number
Brand
Product Description

USP
Meropenem, United States Pharmacopeia (USP) Reference Standard
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Erythromycin, United States Pharmacopeia (USP) Reference Standard
Supelco
Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material
Metronidazole, European Pharmacopoeia (EP) Reference Standard
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
Ceftazidime, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Supelco
Metronidazole, analytical standard
Sigma-Aldrich
Metronidazole, BioXtra
Supelco
Aztreonam, analytical standard
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Supelco
Metronidazole, VETRANAL®, analytical standard
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
USP
Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Azithromycin, European Pharmacopoeia (EP) Reference Standard
Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Azithromycin, United States Pharmacopeia (USP) Reference Standard
USP
Amoxicillin, United States Pharmacopeia (USP) Reference Standard
USP
Aztreonam, United States Pharmacopeia (USP) Reference Standard
Supelco
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Levofloxacin, analytical standard
USP
Cefixime, United States Pharmacopeia (USP) Reference Standard
Supelco
Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin, VETRANAL®, analytical standard